BioCrossroads
@biocrossroads
BioCrossroads focuses on investment, development and advancement of Indiana's signature life sciences strengths
ID: 14885302
http://www.biocrossroads.com 23-05-2008 19:08:42
6,6K Tweet
2,2K Followers
803 Following

Please join us in welcoming Amanda Decker to BioCrossroads as our Director of Communications. We are thrilled to have her join our small but mighty team, starting next week!

Our colleagues Conexus Indiana have an awesome program to recognize rising stars in Indiana's #advancedmanufacturing and #logistics space. Nominations for 𝗥𝗶𝘀𝗶𝗻𝗴 𝟯𝟬 are 𝗢𝗣𝗘𝗡 now! Nominate a rising star here: conexusindiana.formstack.com/forms/30_under…

Need another example of the #innovation happening in #IndianaLifeSciences? Vital Views Technologies could help millions of heart patients. Thanks to Kylie Veleta Inside INdiana Business for the spotlight. insideindianabusiness.com/articles/5m-bo…
Congratulations to Dr. Philip Low and his On Target Laboratories, Inc. on the close of a $30M series C funding round. #Cytalux Purdue Research Foundation insideindianabusiness.com/articles/start…
Fascinating. A team of Indiana University researchers may have broken ground by integrating human brain tissue into their new computer. #Brainoware popsci.com/technology/bra…
Great segment from Kylie Veleta on @IIBTV about a cancer treatment advance discovered - and soon to be made - in Indiana. Novartis Purdue Chemistry insideindianabusiness.com/articles/cance…

Congratulations to Carmel's Sudo Biosciences on earning $116 million to advance two lead drug candidates into human testing next year. And to @IBJNews' John Russell on the scoop. bit.ly/3TyDa4R

Know a young professional in the advanced manufacturing and logistics industry? Conexus Indiana is looking for nominations for its 30 under 30 class, Rising 30. Deadline is Jan. 12. conexusindiana.formstack.com/forms/30_under…

Need another example of the #innovation happening in #IndianaLifeSciences? #VitalViewTechnologies could help millions of heart patients. Great spotlight from Inside INdiana Business's Kylie Veleta. insideindianabusiness.com/articles/5m-bo…
Congrats to IU School of Medicine's Mark R. Kelley on the positive Phase 2 trial results of a first-of-its-kind drug he developed – APX3330 - to slow the progression of diabetic retinopathy for patients in earlier stages of the disease. blogs.iu.edu/iuimpact/2023/…
